Molecular Subtypes Guide HIPEC Drug Choices in Colorectal Cancer
Publication Title: ASO Visual Abstract: Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases
Summary
- Question
- This study examined whether consensus molecular subtype (CMS) classification, a system that categorizes colorectal cancer (CRC) tumors based on genetic activity patterns, could guide the selection of the most effective chemotherapy agents for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colorectal cancer peritoneal metastases (CRC-PM).
- Why it Matters
- CRC-PM is a severe form of cancer where tumors spread to the lining of the abdomen, and treatment often involves HIPEC, a procedure that delivers heated chemotherapy directly to the abdominal cavity. However, there is no clear consensus on which chemotherapy agents work best. This research is important because it aims to personalize treatment by matching chemotherapy agents to tumor subtypes, potentially improving outcomes for patients and reducing unnecessary toxicity.
- Methods
- The researchers analyzed 34 CRC cell lines, which are lab-grown tumor cells used to study cancer, representing the four CMS subtypes. They tested these cells against five commonly used HIPEC chemotherapy agents: mitomycin C, irinotecan, oxaliplatin, cisplatin, and 5-fluorouracil. The goal was to determine how each CMS subtype responded to these drugs.
- Key Findings
- The study found that tumors classified as CMS4, which make up over 80% of CRC-PM cases, were more sensitive to mitomycin C and irinotecan compared to oxaliplatin, cisplatin, and 5-fluorouracil. This suggests that CMS4 tumors have distinct biological characteristics that make them respond better to specific drugs.
- Implications
- These findings suggest that CMS classification could help doctors choose the most effective chemotherapy agents for individual patients undergoing HIPEC for CRC-PM. By tailoring treatment based on tumor subtype, healthcare providers could improve patient outcomes, minimize side effects, and use medical resources more efficiently.
- Next Steps
- The authors recommended conducting clinical trials to validate these findings in real-world patient settings. Further research is needed to explore how CMS classification could be integrated into clinical practice to personalize treatment for CRC-PM.
- Funding Information
- This research was supported by the National Medical Research Council (NMRC), grants from the Colonel Daniel Connelly Memorial Fund, the Andrew Sabin Family Fellowship Award, the Cancer Prevention & Research Institute of Texas (RR180035 and RP240392), and the Appendiceal Cancer Pseudomyxoma Peritonei Research Foundation (Catalyst Research Grant). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Yale University also provided funding and support for this research.
Full Citation
Gupta P, Godfrey E, Schultz K, Qiao L, Aguirre N, Bader J, Foote M, Shen J, Shergill A, Cecchini M, Sundar R, Sheltzer J, Turaga K. ASO Visual Abstract: Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases. Annals Of Surgical Oncology 2026, 33: 6200-6201. PMID: 41735726, DOI: 10.1245/s10434-026-19269-x.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Princy Gupta
First AuthorKiran Turaga, MD, MPH
Last AuthorProfessor of Surgery (Oncology)